The overall high content screening market is expected to grow from USD 506.7 million in 2016 to USD 909.0 million by 2022, at a CAGR of 10.3% from 2017 to 2022.
The major factors driving the growth of the HTS market include initiatives undertaken by pharmaceutical and biotechnology companies, increasing R&D spending, technological advancements in HTS, and the availability of government funding and venture capital investments.
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391
High Content Screening Market is segmented into following types:
* High-content screening (HCS) is a method that is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. High-content screening includes any method used to analyze whole cells or components of cells with a simultaneous readout of several parameters.
* Based on product, the global market is broadly segmented into instruments, consumables, software, services, and accessories. The market for HCS software is expected to grow at the highest CAGR between 2017 and 2022. Among all high content screening products, instrument segment caters to the largest share. The large share of this segment is attributed to advances in instrumentation and automation techniques and high prices of HCS instruments.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=42710391
Some of The Major Players In High Content Screening Market :
1. GE Healthcare (U.S.)
2. Danaher Corporation (U.S.)
3. Thermo Fisher Scientific, Inc. (U.S.)
4. PerkinElmer, Inc. (U.S.)
5. Tecan Group (Switzerland)
6. BioTek Instruments Inc. (U.S.)
7. Becton, Dickinson and Company (U.S.)
8. Bio-Rad Laboratories (U.S.)
The factors expected to drive the growth of the market are rising need for cost containment in pharmaceutical R&D, growth in funding for cellular research, and technological advancements in HCS solutions during the forecast period. The increasing number of contract research organizations providing HCS outsourcing services and application of HCS in personalized medicine offer significant growth opportunities in the HCS market. The rising adoption of label-free technologies and growing focus on stem cell analysis are the key trends in the HCS market.
The major factors driving the growth of the HTS market include initiatives undertaken by pharmaceutical and biotechnology companies, increasing R&D spending, technological advancements in HTS, and the availability of government funding and venture capital investments.
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391
High Content Screening Market is segmented into following types:
* High-content screening (HCS) is a method that is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. High-content screening includes any method used to analyze whole cells or components of cells with a simultaneous readout of several parameters.
* Based on product, the global market is broadly segmented into instruments, consumables, software, services, and accessories. The market for HCS software is expected to grow at the highest CAGR between 2017 and 2022. Among all high content screening products, instrument segment caters to the largest share. The large share of this segment is attributed to advances in instrumentation and automation techniques and high prices of HCS instruments.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=42710391
Some of The Major Players In High Content Screening Market :
1. GE Healthcare (U.S.)
2. Danaher Corporation (U.S.)
3. Thermo Fisher Scientific, Inc. (U.S.)
4. PerkinElmer, Inc. (U.S.)
5. Tecan Group (Switzerland)
6. BioTek Instruments Inc. (U.S.)
7. Becton, Dickinson and Company (U.S.)
8. Bio-Rad Laboratories (U.S.)
The factors expected to drive the growth of the market are rising need for cost containment in pharmaceutical R&D, growth in funding for cellular research, and technological advancements in HCS solutions during the forecast period. The increasing number of contract research organizations providing HCS outsourcing services and application of HCS in personalized medicine offer significant growth opportunities in the HCS market. The rising adoption of label-free technologies and growing focus on stem cell analysis are the key trends in the HCS market.
No comments:
Post a Comment